The results of "2022 China's Medical Enterprises with 10 Times Growth Potential" were announced.

Beijing CytoNiche Biotechnology Co., Ltd.,

with its original 3D cell "intelligent" manufacturing technology,

was ranked into the list of [Biomedicine and Supporting Industries].

Taking in to account the impact of the international environment and the epidemic, under the background of the accelerated implementation of "Healthy China" strategy, this survey focused on the health care field with the attributes of both "key technology" and "anti-cycle", targeted at the enterprises in the fields of biomedicine and its supporting industries, medical devices and supporting industries, digital health and synthetic biology, selected the innovative enterprises with 10 times growth potential in revenue, sales volume and product matrix in each sector in the future.

During the profound changes, as the enterprise of a new generation, CytoNiche has created 3D FloTrix® Cell Technology Platform through the transformation of original research achievements, with the vision of opening a new era of cell industrial development, focuses on the pain points of the industry, breaks through the technological bottlenecks, so as to change the inherent pattern of the medical industry through innovative products and services. Meanwhile, it also shows the unique charm of the super growth after the difficult R&D process in the early stage, which is favored by the industry and investors.

[CytoNiche]

Beijing CytoNiche Biotechnology Co., Ltd. was established by the research team of Professor Du Yanan from Tsinghua University School of Medicine, and was jointly established by Tsinghua University through equity participation. The core technologies were derived from the transformation of scientific and technological achievements of Tsinghua University. CytoNiche focuses on building an original 3D cell "smart manufacturing" platform, as well as providing overall solutions for the 3D microcarrier-based customized cell amplification process.

CytoNiche's core product, 3D TableTrix® Microcarrier Tablet (Microcarrier), is an independent innovation and the first pharmaceutical excipient grade microcarrier that can be used for cell drug development. It has obtained the certificate of analysis from relevant authoritative institutions such as National Institutes for Food and Drug Control, and obtained 2 qualifications for pharmaceutical excipients from the National Medical Products Administration (CDE approval registration number: F20210000003, F20210000496). Moreover, the product has obtained the DMF qualification for pharmaceutical excipients from U.S. FDA (DMF: 35481). 

Products and services of CytoNiche can be widely used in the upstream process development of gene and cell therapy, extracellular vesicles, vaccines, and protein products. At the same time, it also has broad prospects for applications in the fields of regenerative medicine, organoids, and food technology (cell-cultured meat, etc.).

Our company has a R&D and transformation platform of 5,000 square meters, including a CDMO platform of more than 1,000 square meters, a GMP production platform of 4,000 square meters, and a new 1200 L microcarrier production line. The relevant technologies have obtained more than 100 patents and more than 30 articles about the technologies in international journals have been published. The core technology projects have obtained a number of national-level project support and applications.